ストックスクリーナーアプリを入手
19.94
3.06%
-0.63
アフターアワーズ：
19.94
前日終値:
$20.57
開ける：
$20.69
24時間の取引高:
196.72K
Relative Volume:
0.45
時価総額：
$739.69M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+3.10%
1か月 パフォーマンス:
-14.90%
6か月 パフォーマンス:
+70.43%
1年 パフォーマンス:
-10.66%
1日の値動き範囲:
$19.80
$20.71
1週間の範囲:
$18.78
$21.95
52週間の値動き範囲:
$10.01
$26.04
Ceribell Inc Stock (CBLL) Company Profile
Compare CBLL vs ABT, SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CBLL
Ceribell Inc
|
19.94 | 763.06M | 0 | 0 | 0 | 0.00 |
|
ABT
Abbott Laboratories
|
111.47 | 197.52B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
SYK
Stryker Corp
|
365.85 | 139.09B | 25.12B | 3.25B | 4.28B | 8.4018 |
|
MDT
Medtronic Plc
|
100.88 | 129.59B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
BSX
Boston Scientific Corp
|
74.12 | 108.96B | 20.08B | 2.89B | 3.82B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
76.44 | 46.04B | 6.07B | 1.06B | 799.60M | 1.8527 |
Ceribell Inc Stock (CBLL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-21 | 開始されました | Raymond James | Strong Buy |
| 2025-06-24 | 開始されました | BTIG Research | Buy |
| 2025-04-04 | 開始されました | Ladenburg Thalmann | Buy |
| 2024-11-05 | 開始されました | BofA Securities | Buy |
| 2024-11-05 | 開始されました | Canaccord Genuity | Buy |
| 2024-11-05 | 開始されました | JP Morgan | Overweight |
| 2024-11-05 | 開始されました | TD Cowen | Buy |
| 2024-11-05 | 開始されました | William Blair | Outperform |
すべてを表示
Ceribell Inc (CBLL) 最新ニュース
Market Overview: How sensitive is CeriBell Inc to inflation2025 Price Targets & Weekly Return Optimization Alerts - baoquankhu1.vn
FMR LLC Reduces Stake in CeriBell Inc: A Strategic Portfolio Adj - GuruFocus
Ceribell to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 - The Manila Times
Ceribell Inc introduces new neonatal EEG at NEO Pediatrix event - Traders Union
Ceribell, Inc. shows power of POCEEG in seizure detection - Traders Union
Ceribell CEO Chao Xingjuan sells $786k in shares - Investing.com
CeriBell (NASDAQ:CBLL) VP David Foehr Sells 5,556 Shares - MarketBeat
New medical partner - Northwest Indiana Business Magazine
What are the future prospects of CeriBell IncPortfolio Update Summary & Risk Controlled Swing Trade Alerts - baoquankhu1.vn
What is CeriBell Incs 5 year growth outlook2025 Dividend Review & Trade Opportunity Analysis Reports - baoquankhu1.vn
What is CeriBell Inc. s revenue forecastJuly 2025 Breakouts & Weekly Return Optimization Alerts - mfd.ru
Ceribell: Strong Clinical Integration and AI-Driven Differentiation Support Buy Rating and High-Growth Outlook - TipRanks
BTIG Reiterates Buy Rating for CeriBell (CBLL) with $30 Price Ta - GuruFocus
Forecasting The Future: 5 Analyst Projections For CeriBell - Benzinga
Income Plays: Is CeriBell Inc a top pick in the sectorWeekly Loss Report & Community Trade Idea Sharing Platform - baoquankhu1.vn
Fed Meeting: What are the risks of holding CeriBell Inc2025 Top Gainers & Expert Curated Trade Ideas - baoquankhu1.vn
What’s the profit margin of CeriBell Inc.Analyst Upgrade & Safe Entry Trade Reports - mfd.ru
CeriBell, Inc. $CBLL Shares Acquired by Emerald Mutual Fund Advisers Trust - MarketBeat
Ceribell director resigns to pursue other professional ventures - MSN
CeriBell, Inc. (CBLL) Stock Analysis: A 24% Potential Upside Beckons in the Dynamic Medical Device Sector - DirectorsTalk Interviews
Targets Report: Is Bolt Projects Holdings Inc stock a buy or sellPortfolio Return Summary & Entry and Exit Point Strategies - baoquankhu1.vn
Ceribell director Parvizi sells $573k in shares By Investing.com - Investing.com South Africa
Josef Parvizi Sells 25,000 Shares of CeriBell (NASDAQ:CBLL) Stock - MarketBeat
Ceribell director Parvizi sells $573k in shares - Investing.com
CeriBell a new buy at BTIG on growth in EEG monitoring system - MSN
FDA clearances: Siemens Healthineers, Medtronic, CeriBell - Modern Healthcare
Risk Hedge: Does CeriBell Inc stock reflect fundamentalsJuly 2025 Levels & Daily Chart Pattern Signal Reports - baoquankhu1.vn
CeriBell Maps 2026 Growth at JPMorgan MedTech, Eyes Delirium and Stroke EEG Expansion - Yahoo Finance
Growth Value: Does CeriBell Inc have consistent dividend growthAnalyst Downgrade & Real-Time Market Trend Scan - baoquankhu1.vn
Protara, Ceribell rise on FDA breakthrough designations - MSN
CBLL: FDA-cleared AI neuromonitoring expands to pediatrics and delirium, driving growth and efficiency - TradingView
CBLL: 2026 growth will accelerate with new FDA clearances, VA expansion, and pediatric launches - TradingView — Track All Markets
Ceribell sues Natus Medical for patent infringement - MSN
CeriBell, Inc. (NASDAQ:CBLL) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Ceribell shares advance after FDA grants breakthrough device status - MSN
CeriBell, Inc.'s (NASDAQ:CBLL) Shares May Have Run Too Fast Too Soon - simplywall.st
Is CeriBell Inc. stock a buy on dips2025 Top Decliners & Long-Term Safe Return Strategies - Улправда
Is CeriBell Inc. stock attractive for retirement portfoliosOptions Play & AI Driven Price Predictions - ulpravda.ru
Will CeriBell Inc. stock rally after Fed decisions2025 Key Highlights & Reliable Intraday Trade Plans - ulpravda.ru
Aug Technicals: Why CeriBell Inc. stock could outperform in 2025Portfolio Risk Summary & High Return Trade Opportunity Guides - ulpravda.ru
FDA clearances and approvals: J&J, Abbott, Edwards Lifesciences - Modern Healthcare News
Ceribell’s Foehr sells $125k in shares after option exercise By Investing.com - Investing.com Nigeria
Xingjuan Chao Sells 79,000 Shares of CeriBell (NASDAQ:CBLL) Stock - MarketBeat
Ceribell CEO Chao Xingjuan sells $1.68 million in shares By Investing.com - Investing.com South Africa
Ceribell CEO Chao Xingjuan sells $1.68 million in shares - Investing.com
Pittsburgh Post-GazetteCeriBell, Inc.Common Stock (Nasdaq:CBLL) Detailed Stock Data - FinancialContent
Ceribell’s Foehr sells $125k in shares after option exercise - Investing.com
Will CeriBell Inc. stock benefit from infrastructure spendingFootwear buying guidance for recovery days and low impact training focuses on balanced cushioning and support, making it a solid option for daily use. - ulpravda.ru
Ceribell Gets FDA Breakthrough Device Status - Medical Device and Diagnostic industry
Ceribell’s AI Stroke Detection Tool Gains FDA Breakthrough Status - Zenopa
CBLL Wins FDA Breakthrough Status for AI-Based LVO Stroke Detection - Yahoo Finance
Ceribell Inc (CBLL) 財務データ
Ceribell Inc (CBLL) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
0.45%
0.31%
大文字化:
|
ボリューム (24 時間):